These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 341110)

  • 81. Assessment and treatment of obsessive-compulsive disorder in children.
    Wolff RP; Wolff LS
    Behav Modif; 1991 Jul; 15(3):372-93. PubMed ID: 1953625
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Comparative study of three psychotropics for treatment of depressions].
    de Sousa MP; Lopes JS; Figueira L; Cardoso JN
    Int Pharmacopsychiatry; 1976; 11(1):43-64. PubMed ID: 4407
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Differences in the effects of clomipramine on English and Asian volunteers. Preliminary report on a pilot study.
    Allen JJ; Rack PH; Vaddadi KS
    Postgrad Med J; 1977; 53 Suppl 4():79-86. PubMed ID: 341109
    [No Abstract]   [Full Text] [Related]  

  • 84. Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response.
    Vandel B; Vandel S; Jounet JM; Allers G; Volmat R
    Eur J Clin Pharmacol; 1982; 22(1):15-20. PubMed ID: 7094971
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Increased antipanic efficacy in combined treatment with clomipramine and dixyrazine.
    Feet PO; Götestam KG
    Acta Psychiatr Scand; 1994 Apr; 89(4):230-4. PubMed ID: 7912879
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Behavioural psychotherapy to encourage self-treatment of a patient with an obsessive-compulsive neurosis.
    Eveleigh C
    Nurs Times; 1977 Jul; 73(27):1036-8. PubMed ID: 196260
    [No Abstract]   [Full Text] [Related]  

  • 87. The role of intravenous clomipramine in the treatment of obsessional and phobic disorders.
    Marshall WK; Micev V
    Scott Med J; 1975; 20(1 SUPPL):49-53. PubMed ID: 1154014
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The behavioural treatment of obsessional-compulsive disorders, with and without clomipramine.
    Rachman S; Cobb J; Grey S; McDonald B; Mawson D; Sartory G; Stern R
    Behav Res Ther; 1979; 17(5):467-78. PubMed ID: 508227
    [No Abstract]   [Full Text] [Related]  

  • 89. Determination of clomipramine and desmethylclomipramine in plasma by means of liquid chromatography.
    Westenberg HG; Drenth BF; de Zeeuw RA; de Cuyper H; van Praag HM; Korf J
    J Chromatogr; 1977 Nov; 142():725-33. PubMed ID: 914945
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis.
    Cox BJ; Swinson RP; Morrison B; Lee PS
    J Behav Ther Exp Psychiatry; 1993 Jun; 24(2):149-53. PubMed ID: 8263222
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Some observations on patient compliance in an antidepressive trial.
    Witts DJ; Mulgirigama D; Turner P; Pare CM
    Postgrad Med J; 1977; 53 Suppl 4():136-8. PubMed ID: 341102
    [No Abstract]   [Full Text] [Related]  

  • 92. Discontinuing obsessive-compulsive disorder medication with behavior therapy.
    Baer L; Ricciardi J; Keuthen N; Pettit AR; Buttolph ML; Otto M; Minichiello W; Jenike MA
    Am J Psychiatry; 1994 Dec; 151(12):1842. PubMed ID: 7977900
    [No Abstract]   [Full Text] [Related]  

  • 93. The neurobiology of obsessive-compulsive disorder.
    Rapoport JL
    JAMA; 1988 Nov; 260(19):2888-90. PubMed ID: 3184353
    [No Abstract]   [Full Text] [Related]  

  • 94. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals.
    Marks IM; Lelliott P; Basoglu M; Noshirvani H; Monteiro W; Cohen D; Kasvikis Y
    Br J Psychiatry; 1988 Apr; 152():522-34. PubMed ID: 3167404
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Single versus divided daily dosages of clomipramine. Plasma concentration and clinical effect.
    Dencker SJ; Nagy A
    Acta Psychiatr Scand; 1979 Mar; 59(3):326-34. PubMed ID: 373391
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Are gender differences in antiobsessional response related to different clomipramine metabolism?
    Mundo E; Pirola R; Bellodi L; Smeraldi E; Bareggi SR
    J Clin Psychopharmacol; 2002 Jun; 22(3):341-2. PubMed ID: 12006911
    [No Abstract]   [Full Text] [Related]  

  • 97. Inert placebo versus active medication. Patient blindability in clinical pharmacological trials.
    Bystritsky A; Waikar SV
    J Nerv Ment Dis; 1994 Sep; 182(9):485-7. PubMed ID: 8083675
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The impact of clomipramine and its withdrawal on some nocturnal hormone profiles--a preliminary report.
    Lacey JH; Crisp AH; Groom GV; Seldrup J
    Postgrad Med J; 1977; 53 Suppl 4():182-9. PubMed ID: 341106
    [No Abstract]   [Full Text] [Related]  

  • 99. A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting).
    Leonard HL; Lenane MC; Swedo SE; Rettew DC; Rapoport JL
    Arch Gen Psychiatry; 1991 Sep; 48(9):821-7. PubMed ID: 1929772
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The management of phobic disorders using clomipramine (Anafranil).
    Waxman D
    J Int Med Res; 1977; 5(1 Suppl):24-31. PubMed ID: 324831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.